Brought to you by 
GemVax Technology takes a 42% stake in NovaHep
13 May 2015
Executive Summary
GemVax Technology Co. Ltd. acquired a controlling interest in privately held regenerative medicine firm NovaHep AB through the purchase of 90.4k shares (valued at about $1.77mm).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GemVax Technology takes a 42% stake in NovaHep
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice